The ability of fluconazole to penetrate into ventilated, healthy and inflamed lung tissue in a model of severe sepsis in rats

Pharmacology

Volumn 87, Issue 3-4, 2011, Pages 130-134

  Mauric, Oliver ^a   Thallinger, Christiane ^a   Kugler, Sylvia A ^a   Joukhadar, Samir M ^a   Kovar, Florian M ^a   Konz, Karl H ^b   Graninger, Wolfgang ^a   Joukhadar, Christian ^a,c,d,e  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KLINIKEN MARIA HILF GMBH   (Germany)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e J & P Medical Research Ltd   (Austria)

Author keywords

Fluconazole; Rats; Tissue penetration

Indexed keywords

FLUCONAZOLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MUSCLE LEVEL; DRUG PENETRATION; DRUG TISSUE LEVEL; HUMAN; HUMAN TISSUE; LUNG PARENCHYMA; MALE; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PNEUMONIA; PRIORITY JOURNAL; RAT; SEPSIS; SINGLE DRUG DOSE; SKELETAL MUSCLE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTIFUNGAL AGENTS; BLOOD PROTEINS; DISEASE MODELS, ANIMAL; EXTRACELLULAR SPACE; FLUCONAZOLE; INJECTIONS, INTRAVENOUS; LIPOPOLYSACCHARIDES; LUNG; MALE; MICRODIALYSIS; MUSCLE, SKELETAL; PROTEIN BINDING; RATS; RATS, WISTAR; SEPSIS; SEVERITY OF ILLNESS INDEX; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 79955122470     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000323738     Document Type: Article

References (14)

1. Joukhadar C, Frossard M, Mayer BX, Brunner M, Klein N, Siostrzonek P, Eichler HG, Müller M: Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001; 29: 385-391. (Pubitemid 32171786)
2. Tomaselli F, Maier A, Matzi V, Smolle-Jüttner FM, Dittrich P: Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis. Antimicrob Agents Chemother 2004; 48: 2228-2232. (Pubitemid 38691623)
3. Joukhadar C, Thallinger C, Pöppl W, Kovar F, Konz KH, Joukhadar SM, Traunmüller F: Concentrations of voriconazole in healthy and inflamed lung in rats. Antimicrob Agents Chemother 2009; 53: 2684-2686.
4. Skhirtladze K, Hutschala D, Fleck T, Thalhammer F, Ehrlich M, Vukovich T, Müller M, Tschernko EM: Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother 2006; 50: 1372-1375.
5. Joukhadar C, Müller M: Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future. Clin Pharmacokinet 2005; 44: 895-913. (Pubitemid 41252841)
6. Sauermann R, Delle-Karth G, Marsik C, Steiner I, Zeitlinger M, Mayer-Helm BX, Georgopoulos A, Müller M, Joukhadar C: Pharmacokinetics and pharmacodynamics of cefpirome in subcutaneous adipose tissue of septic patients. Antimicrob Agents Chemother 2005; 49: 650-655. (Pubitemid 40175676)
7. Brammer KW, Farrow PR, Faulkner JK: Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990; 12(suppl 3):S318-S326. (Pubitemid 20125727)
8. Ip M, Au C, Cheung SW, Chan CY, Cheng AF: A rapid high-performance liquid chromatographic assay for cefepime, fluconazole and meropenem. J Antimicrob Chemother 1998; 42: 121-123. (Pubitemid 28356378)
9. Traunmüller F, Schintler MV, Metzler J, Spendel S, Mauric O, Popovic M, Konz KH, Scharnagl E, Joukhadar C: Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother 2010; 65: 1252-1257.
10. Mikamo H, Kawazoe K, Sato Y, Izumi K, Ito T, Ito K, Tamaya T: Penetration of oral fluconazole into gynecological tissues. Antimicrob Agents Chemother 1999; 43: 148-151. (Pubitemid 29069214)
11. Shrikhande S, Friess H, Issenegger C, Martignoni ME, Yong H, Gloor B, Yeates R, Kleeff J, Büchler MW: Fluconazole penetration into the pancreas. Antimicrob Agents Chemother 2000; 44: 2569-2571. (Pubitemid 30650921)
12. Cronin S, Chandrasekar PH: Safety of triazole antifungal drugs in patients with cancer. J Antimicrob Chemother 2010; 65: 410-416.
13. Su YC, Sheu YT, Peng MY, Yeh KM, Huang CY, Wang SM, Chang YF, Chang MC, Wu MF, Tsao SM: An observational study on the empiric use of fluconazole in febrile neutropenia. J Microbiol Immunol Infect 2007; 40: 62-67.
14. Yamazaki H, Nakamoto M, Shimizu M, Murayama N, Niwa T: Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. Br J Clin Pharmacol 2010; 69: 593-597.